KIT mutations

GPTKB entity

Statements (63)
Predicate Object
gptkbp:instance_of gptkb:physicist
gptkbp:bfsLayer 5
gptkbp:bfsParent gptkb:Iclusig
gptkb:Avapritinib
gptkbp:affects tyrosine kinase activity
gptkbp:analyzes animal models
targeted therapies
therapeutic targets
biomarker potential
gptkbp:associated_with gptkb:healthcare_organization
Gastrointestinal stromal tumors
mastocytosis
gptkbp:can_lead_to tumor growth
gptkbp:caused_by gain-of-function
gptkbp:descendant in some cases
gptkbp:examines survival rates
clinical outcomes
molecular studies
gptkbp:has_influence_on treatment response
https://www.w3.org/2000/01/rdf-schema#label KIT mutations
gptkbp:is_aimed_at gptkb:imatinib
gptkb:sunitinib
gptkb:regorafenib
gptkbp:is_analyzed_in longitudinal studies
pathology reports
mutation frequency
gptkbp:is_associated_with disease progression
resistance to therapy
gptkbp:is_characterized_by gptkb:municipality
gptkbp:is_considered driver mutations
a focus of ongoing research.
important in oncology research
gptkbp:is_discussed_in scientific reviews
gptkbp:is_documented_in genetic databases
gptkbp:is_evaluated_by clinical significance
gptkbp:is_explored_in genetic counseling
gptkbp:is_found_in exon 11
exon 9
exon 17
gptkbp:is_linked_to increased cell proliferation
poor prognosis
metastatic disease
adverse effects of treatment
increased survival of cancer cells
gptkbp:is_noted_for gptkb:academic_journal
gptkbp:is_often_compared_to gptkb:Person
older adults
gptkbp:is_often_used_in certain cancers
gptkbp:is_part_of molecular diagnostics
cancer genomics
precision medicine approaches
gptkbp:is_recognized_by biopsy samples
gptkbp:is_studied_in clinical trials
pharmacogenomics
therapeutic resistance mechanisms
therapeutic implications
gptkbp:is_subject_to regulatory approval
gptkbp:is_tested_for research studies
gptkbp:occurs_in somatic cells
germline
gptkbp:recognizes genetic testing
gptkbp:reports_to case studies
gptkbp:resulted_in abnormal cell signaling